Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BE SURE: Bimekizumab vs Adalimumab in Moderate to Severe Chronic Plaque Psoriasis
NCT03412747Phase 3Completed
- Sponsor
- UCB
- Start
- Jan 2018
- Primary completion
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 9
01
Overview
A Phase 3 trial of bimekizumab in psoriasis, sponsored by UCB. Started Jan 2018; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriasis
Beyond the preview
Go deeper on NCT03412747.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03412747.